eyenovia-logo 3

News Release

Printer Friendly Version View printer-friendly version
<< Back
Eyenovia to Present at the Ladenburg Thalmann 2018 Healthcare Conference

NEW YORK, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver microdosed medications topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer, is scheduled to present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018 at The Sofitel New York Hotel.

Details of the presentation are below:

Event: Ladenburg Thalmann 2018 Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 10:30am ET
Location: Track 3 - St. Germain II

About Eyenovia
Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, glaucoma and other eye diseases.

Company Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
[email protected]

Investor Contact:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: 646-536-7035/7037
[email protected] / [email protected]

Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]

Eyenovia Logo 311 x 109.png

Eyenovia, Inc.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

New York    501 Fifth Avenue, Suite 1404 New York NY 10017     +1 (917) 289-1117

[email protected]